MRTNZ

MRTNZ Investment Office · S&P 500 · The 360 Vantage

IQV · NYSE

IQVIA Holdings, Inc.

Health Care · Biotechnology: Commercial Physical & Biological Resarch

Reference price$240.67As of Jul 30, 2026
Market capitalization$39.61B
52-week range$154.50–$251.36
S&P 500 portfolio weight0.06%
Data qualitycomplete

Street view

Analyst targets

Published sell-side aggregation—not an MRTNZ forecast.

Low$230.00-4.4% vs. reference
Average$269.85+12.1% vs. reference
High$300.00+24.7% vs. reference
13 Buy1 Hold0 Sell

Forward calendar

Current earnings expectations

Consensus may change until the company reports.

Expected reportNot availableSep 2026
Consensus EPS$2.956 estimates
Expected range$2.86–$3.09Low to high EPS
Dec 2026$11.57Street EPS consensus
Dec 2027$12.93Street EPS consensus
Dec 2028$14.57Street EPS consensus

Reported results

Annual financial snapshot

Fiscal period ended Dec 31, 2025.

MetricCurrentPrior
Revenue+5.9% YoY$16.31B$15.41B
Operating income$2.18B$2.2B
Net income$1.36B$1.37B
Operating cash flow$2.65B$2.72B
Capital expenditures($0.6B)($0.6B)

Current context

Related news

Company-linked articles surfaced by Nasdaq.

Barchart

Stocks Settle Mostly Higher on Positive Earnings Results

Zacks

WM Earnings Beat on Pricing in Q2, Revenues Miss Estimates

Zacks

Verisk Earnings Surpass Estimates in Q2 on Insurance Growth

Evidence

Sources & method

Nasdaq quote →Nasdaq summary →Earnings forecast →Annual financials →Official S&P 500-tracking holdings →

Facts, estimates, and scenarios are kept separate. Analyst targets and EPS expectations are third-party estimates, not MRTNZ forecasts. Index weight uses the official IVV portfolio as the denominator. Illustrative research, not investment advice.